Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:THOR

Synthorx (THOR) Stock Price, News & Analysis

Synthorx logo

About Synthorx Stock (NASDAQ:THOR)

Advanced Chart

Key Stats

Today's Range
$67.99
$67.99
50-Day Range
$67.99
$67.99
52-Week Range
$11.05
$71.90
Volume
N/A
Average Volume
474,507 shs
Market Capitalization
$2.20 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Synthorx, Inc., a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. It also develops IL-2 Synthorin for autoimmune indications; IL-10 Synthorin, a naturally occurring immune cell growth factor in humans for the treatment of immuno-oncology (IO); and IL-15 Synthorins, an immunoregulatory cytokine to treat IO. In addition, the company develops other Synthorin programs targeting undisclosed cytokines that play critical roles in the orchestration of anti-tumor responses by innate and adaptive immune cells. The company was formerly known as Alinos, Inc. and changed its name to Synthorx, Inc. in March 2014. Synthorx, Inc. was founded in 2014 and is headquartered in La Jolla, California.

Receive THOR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Synthorx and its competitors with MarketBeat's FREE daily newsletter.

THOR Stock News Headlines

Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Biosimilar Interleukins Global Market Report 2023
See More Headlines

THOR Stock Analysis - Frequently Asked Questions

Synthorx, Inc. (NASDAQ:THOR) issued its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.12.

Synthorx (THOR) raised $100 million in an initial public offering on Friday, December 7th 2018. The company issued 9,100,000 shares at a price of $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Synthorx investors own include Pfizer (PFE), NVIDIA (NVDA), Gilead Sciences (GILD), Meta Platforms (META), Alibaba Group (BABA), Tesla (TSLA) and Salesforce (CRM).

Company Calendar

Last Earnings
11/05/2019
Today
5/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:THOR
Fax
N/A
Employees
48
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-56,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$6.72 per share
Price / Book
10.12

Miscellaneous

Free Float
N/A
Market Cap
$2.20 billion
Optionable
Not Optionable
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:THOR) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners